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1. Introduction 
The impact of antiretroviral therapy (ART) on the natural history of HIV is indisputable, 
resulting in dramatic reductions in morbidity and mortality and improvements in quality of 
life. This recognition coincides with a change in view of HIV infection from a progressive fatal 
disease to a medically manageable chronic condition. However, the requirement for life-long 
therapy with ART has been associated with long-term metabolic toxicities (hyperlipidemia, 
insulin resistance, diabetes, and osteoporosis) and iatrogenic dysmorphias, termed 
lipodystrophy, that have increased the complexity of managing people living with HIV 
infection (PLWH), the manifestations of which include peripheral fat loss and central fat 
accumulation. Lipodystrophy has emerged as one of the most feared complications of ART for 
PLWH. The highly stigmatizing nature of this adverse event has been associated with feelings 
of low self-esteem, forced disclosure of HIV-status, and negative effect on antiretroviral 
adherence. Of more recent significant concern is the finding that the metabolic consequences of 
lipodystrophy and ART, as well as the inflammation caused by the virus, are strong mediators 
for the development of cardiovascular disease (CVD), diabetes, metabolic abnormalities, and 
fatty liver disease and will have important implications for the future health and survival of 
the PLWH. One of the possible mechanisms contributing to these metabolic abnormalities is 
insulin resistance (IR) that has been increasingly seen in PLWH. Interventions aimed at 
improving insulin sensitivity have been shown effective in alleviating some but not all of ART 
and/or HIV associated adverse outcomes. This chapter will review the evidence for IR as a 
potential mechanism involved in HIV-related complications and the role of alternative 
treatments in improving IR in people living with HIV infection. 
2. Metabolic abnormalities associated with HIV infection  
The successful introduction of highly active antiretroviral therapy (HAART), a combination of 
potent antiretroviral agents, including protease inhibitors (PIs), nucleoside reverse 
transcriptase inhibitors (NRTIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs), 
has impacted positively on morbidity and mortality among HIV-positive patients. However, 
over time, HAART has been associated with a number of metabolic and anthropometric 
abnormalities, including dyslipidemia (1-3), hypertension (4-8) and insulin resistance(9-11), as well 
as subcutaneous fat loss and abdominal obesity, all included in the definition of metabolic 
syndrome(12) and potentially contributing to CVD risk . In a cohort of HIV-infected adults (296 
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participants: 217 men and 79 women) of mixed ethnicity with a mean age of 45.3 years, an 
appreciable prevalence of metabolic syndrome (30.0%) has been reported with the frequency 
increasing to 42.5% in those over 50 years of age. More women had abdominal obesity (59.5%) 
than men (20.7%, P<0.001) and the frequency of elevated plasma glucose was also higher in 
females (37.2%) compared to males (16.9%, P=0.004). High frequencies of decreased high-
density lipoprotein cholesterol (HDL-C) and elevated blood pressure were seen in both sexes. 
In those under 50 years of age, the 10-year Framingham coronary heart disease risk score for 
men was double that for women (6.2% vs. 2.7%, P<0.001). In older participants, the risk was 
similar between the sexes, with a third having scores over 10 %( 13). 
These metabolic disturbances are of complex origin, and their development may be affected 
by ART as well as the underlying HIV infection (14). HIV infection itself has been reported to 
impair triglycerides (TG) metabolism and lipoprotein-lipase (LPL) activity, and reduced 
plasma HDL cholesterol, Apo-B and Apo-A1, with higher LDL TG, and higher total 
cholesterol/HDL ratio(1-3-,15). Cytokines, such as interferon alpha, may play a role in the 
abnormal lipid homeostasis seen in PLWH (16,17). The use of PIs has been linked to further 
abnormalities in the serum lipid profile in PLWH (18, 19). Increased total cholesterol (TC), 
TG rich VLDL, and LDL-C are seen in PI-treated patients (19-21). Data from prospective 
cohort studies report new-onset hypercholesterolemia and hypertriglyceridemia after 5 
years of HAART in 24 and 19% of subjects, respectively (22, 23). Individual PIs likely have 
substantially different affects on the lipid profile. Data from the Swiss Cohort study suggest 
that ritonavir, but not indinavir or nelfinavir, is associated with increased TG levels (22). 
Purnell(24) demonstrated significant effects of ritonavir on TG levels after 2 weeks in HIV-
negative patients. Similarly, low dose ritonavir in combination with lopinavir over 4 weeks 
also increased TG levels in HIV-negative men (25). The newer PI atazanavir appears to have 
a significantly less pronounced effect on serum lipid levels (26, 27). The mechanism by 
which PIs influence serum TG is not clear. Animal studies (28, 29) suggest that PIs may 
prevent proteosomal degradation of nascent ApoB, a principle protein component of 
circulating TGs, leading to increased production of VLDL particles. Furthermore, as 
opposed to the “traditional” metabolic syndrome, which involves high free fatty acid (FFA) 
levels due to the inability for appropriate storage into fat cells in the presence of IR, patients 
receiving HAART develop a lipotoxicity due to mitochondrial dysfunction resulting in the 
excess release of FFA (30), resulting in increased production of VLDL and small, dense LDL 
as well as low plasma levels of HDL. This increase in lipolysis appears to cause the 
characteristic subcutaneous lipoatrophy in the face, legs, and buttocks with accumulation of 
fat in the visceral area and the back of the neck. PIs may also induce the lipoatrophy by 
inhibiting sterol regulatory enhancer-binding protein (SREBP-1) (30,31) and peroxisome 
proliferator-activated receptor–γ.(PPAR-γ)(32), which are both involved in lipogenesis.  
Other antiretroviral medications may also affect serum lipids. Kumar(33) reported, in 
treatment-naïve HIV+ subjects, PI sparing regimens (zidovudine/lamivudine + abacavir) 
raised fasting TC and TG least in comparison with regimens containing a PI 
(zidovudine/lamivudine + nelfinavir) or stavudine and a PI. The DAD study (n = 7483 
patients)(34) reported that exposure to non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) is also associated with modest yet significantly increased TG levels (odds ratio, 
1.90; 95% confidence interval, 1.06–3.39), but not with low HDL-C or increased LDL-C.  
Fat redistribution has also been reported frequently in PLWH. NRTIs used to treat HIV-1 
infection are particularly associated with the lipoatrophy in subcutaneous fat (35), whereas 
PIs are considered more likely to cause systemic metabolic alterations such as insulin 
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resistance (36). Non-nucleoside-analog reverse transcriptase inhibitors are not thought to 
contribute to the development of lipodystrophy, although some data have led to a 
reconsideration of the effects of some of these drugs on peripheral fat accumulation (37). 
There have been attempts to treat HIV-1-lipodystrophy using drugs of known effects against 
dyslipidemia (fibrates) or insulin resistance (thiazolidinediones), but results on the overall 
lipodystrophy syndrome have been poor (45,46). 
There is a growing concern about an increased risk for cardiovascular disease (CVD) in 
PLWH especially those receiving ART. This risk could be related to hypertension or 
metabolic abnormalities such as dyslipidemia, diabetes mellitus and central fat deposition 
which are increasingly seen with long-term use of ART (19, 38-41). This is also supported by 
epidemiological studies showing an increased risk for CVD in PLWH (42-44). 
3. Insulin resistance (IR) as one of the possible mechanisms involved 
Insulin resistance a risk factor for CVD is increasingly seen in PLWH and it is often 
accompanied by elevated blood pressure, dysfunctional glucose homeostasis, obesity, and 
dyslipidemia(47,48). It has been shown (49) that the presence of dyslipidemia (i.e. 
hypertriglyceridemia and low plasma HDL concentration) is highly indicative of underlying 
IR in patients with HIV despite fasting normoglycemia. Patients with the HIV-metabolic 
syndrome were also found to have a redistribution of adipose tissue to the intraperitoneal 
compartment and have markedly elevated intrahepatic lipid content (50).  
Insulin resistance is also a component of the lipodystrophy syndrome, and fasting insulin 
levels appear to correlate with waist to hip ratio. Multivariate modeling was used to 
estimate an approximate 1% increase in fasting insulin level for every 1% increase in visceral 
fat or every 1% increase in abdominal subcutaneous fat (51). Insulin levels and IR are higher 
in patients with both peripheral lipoatrophy and visceral adiposity than in those who have 
either alone (52). Intra-abdominal fat delivers excess free fatty acids directly into the portal 
blood system(53) and secrete cytokines and other factors that contribute to IR, impaired 
fibrinolysis(54,55), and endothelial dysfunction leading to increased risk for CVD(56).  
It is unclear whether IR is a direct result of HIV infection alone or it is a complication of 
ART. Chronic infection with HIV may contribute to glucose abnormalities among HIV-
infected patients. In the Multicenter AIDS Cohort Study, insulin resistance markers were 
higher in all groups of HIV-infected men compared with HIV-uninfected control subjects, 
even among those who were not receiving ART (57), suggesting an effect of HIV infection 
itself. A potential factor by which HIV could induce IR is TNF-α, which is chronically 
released by peripheral blood mononuclear cells in PLWH. Systemic inflammation has been 
associated with incident of diabetes in multiple cohorts in the general population (58-60). 
Proinflammatory cytokines, such as tumor necrosis factor (TNF)-α, may induce insulin 
resistance by binding to insulin-responsive elements in skeletal muscle (61). Among HIV-
infected patients, markers of systemic inflammation decrease quickly with ART initiation (62) 
but do not normalize (63). It is speculated that this residual inflammation with effective ART 
may contribute to the pathogenesis of co-morbidities in HIV-infected patients, including 
diabetes (64). 
Insulin resistance could also be a consequence of drug treatments in HIV. Among PLWH on 
ART, an IR prevalence rate of about 20-85% has been reported (9, 10, 65,66). There are 
differences in the pathways through which various PIs induce IR and in their propensity to 
do so. Certain PIs, such as indinavir (IDV), lopinavir, and ritonavir, have been shown to 
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reversibly induce IR, probably by inhibition of glucose translocation through GLUT4 (67). In 
contrast, atazanavir had no effect on IR.The NRTIs, zidovudine and stavudine, also have 
direct and indirect effects on glucose metabolism (68,69). In a case-control study (70), 
comparing 55 previously ART-naive individuals who developed diabetes 48 weeks after 
ART initiation (case subjects) with 55 individuals who did not develop diabetes during a 
comparable follow-up (control subjects), subjects with higher levels of high-sensitivity C-
reactive protein (hs-CRP), soluble TNFR1 (sTNFR1), and sTNFR2 at 48 weeks had an 
increased odds of subsequent diabetes, after adjustment for baseline marker level, age, BMI 
at week 48, CD4 count at week 48, and indinavir use. After further adjustment for week 48 
glucose, effects were attenuated and only sTNFR1 remained significant (odds ratio, highest 
quartile vs. lowest 23.2 [95% CI 1.28–423], P = 0.03). 
Insulin resistance, glucose and lipid metabolism were also found to be directly related to 
circulating adipokines suggesting that abnormalities in adipocytes may contribute to IR in 
patients with HIV. A known side effect of NRTIs is reduction in the production of 
adiponectin by lipoatrophy. Because adiponectin improves insulin sensitivity by increasing 
transportation/oxidation of FFAs and inhibition of hepatic glucose output, 
hypoadiponectinemia due to effects of NRTIs is thought to be a pathway for IR (7). Serum 
adiponectin level has been shown to inversely correlate with fasting insulin concentration 
and with hepatic fat content (71). Adiponectin also has anti-inflammatory properties. It 
suppresses inflammatory cell infiltration of the vascular intimal space (72-74), and 
deficiency of adiponectin up-regulates endothelial adhesion molecules (73). In a study by 
Cade et al(74) who performed adipose tissue biopsies in a cohort of HIV-infected patients, he 
found that the use of PIs is associated with down-regulation of adiponectin mRNA in 
appendicular adipocytes. These findings suggest a mechanistic link between PI use and 
development of dyslipidemia and IR. They also found that patients with HIV-metabolic 
syndrome have blunted insulin-mediated suppression of protein breakdown, unlike 
patients with type 2 diabetes. These findings imply a shared signalling defect in patients 
with HIV-metabolic syndrome that affects lipid, glucose and protein metabolism.  
4. Treatment challenge 
Because HIV infection frequently occurs in young individuals, long-term HAART is necessary 
and, thus, risk-factor modification is increasingly important to prevent the development of 
CVD. There is no single pharmacologic agent available with effects on multiple targets. The 
efficacy and safety of combining anti-inflammatory, antihypertensives, hypoglycemic and 
lipid lowering agents and their interactions with ART must be considered and favourable 
effects on reversing these abnormalities have not been uniformly reported.  
For example, dyslipidemia is common in HIV-infected patients, but treatment outcomes are 
often unsatisfactory. In one study (75) responses to lipid-lowering therapy were compared 
between 829 HIV-infected patients and 6941 uninfected controls, all with laboratory 
evidence of dyslipidemia. The HIV-infected patients had significantly smaller LDL declines 
in response to statins therapy than their HIV-negative counterparts (reduction, 25.6% vs. 
28.3%); within the HIV population, pravastatin was less effective than other agents 
(simvastatin, lovastatin, or atorvastatin). This drug is cited in current guidelines as a 
preferred agent because it has fewer interactions with ART than do other statins. The 
various classes of ART respond to lipid-lowering therapy differently; for example, PIs 
blunted response to fibrate therapy, but NNRTIs did not (75). 
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There have also been attempts to treat HIV-1-lipodystrophy using drugs of known effects 
against dyslipidemia (fibrates) or insulin resistance (thiazolidinediones), but results on the 
overall lipodystrophy syndrome have been poor (45,46). Therefore, drug treatment needs to be 
balanced against the potentially significant drug–drug interactions.  
Until definitive data are available on the efficacy of these medications, the primary focus of 
treatment should be on lifestyle modification, including diet, exercise since they are shown to 
improve IR and CVD risk in the general population. As well, patients with HIV infection have 
been shown to have inadequate dietary intake and suboptimal levels of various micronutrients 
some of which play an important role in regulating insulin function and CVD risk (76-78).  
Therefore, addressing nutritional deficiencies and modifiable risk factors such as smoking, 
obesity, and sedentary lifestyle can have a far greater impact on IR and CVD than changes 
in antiretroviral therapy.  
5. Dietary factors, physical activity and insulin resistance 
The identification of dietary factors that influence energy and lipid metabolism is an 
important research field of nutrition science and has become a growing requirement in the 
context of the HIV/AIDS epidemic in an attempt to attenuate the metabolic abnormalities 
and CVD risk associated with antiretroviral therapy. 
Consumption of energy-dense / high fat diets is strongly and positively associated with the 
overweight state, that in turns induces IR, particularly when the excess body weight is 
located in the abdominal region (79, 80). In patients with HIV infection, we collected 7-day 
food diary from 60 males who also had metabolic abnormalities (77). We estimated their 
energy, macro- and micronutrient intakes and compared it to the Dietary Reference Intakes 
for Canadians. A large proportion (41.5% and 63.1%) of subjects had intakes of fat and 
saturated fat exceeding the recommended levels of intake. None of the subjects met the 
recommended level of intake for fiber and 90.8% did not meet the recommended levels of 
intake for vitamin E. These findings have also been confirmed in other studies (79, 81). 
Dietary fat quality: IR is also independently affected by the type of dietary fat. In animal 
studies, saturated fat increases whereas omega-3 polyunsaturated fatty acids (PUFA) from 
fish and seafood reduce IR (82, 83). Several human studies (84-91) have also shown that saturated 
fat is significantly associated with worsening of IR, independent of body fat, while 
monounsaturated and PUFA improves IR. Based on fatty acid composition in plasma and 
muscle, studies also consistently show that increased unsaturated fat intake is associated 
with improved insulin sensitivity (91-94). Reports from systematic reviews (95, 96) also 
concluded that omega-3 PUFA reduce IR and serum triglycerides. Based on this, the 
American Diabetes Association (97) and American Heart Association (98) have recommended 
the consumption of 2-3 servings of fish/week. In one of our ongoing study (unpublished 
data) in males with HIV infection (n=27) who were found to have non-alcoholic fatty liver 
disease and several metabolic abnormalities, the omega-3 index (a combination of 2 long-
chain omega-3 PUFA, Eicosapentaenoic acid and Docosahexaenoic acid) in the red blood 
cells was significantly lower when compared to HIV-negative male subjects (n=6) with 
minimal findings in their liver biopsies (3.44±0.35 vs. 6.20±1.15; P=0.022). This was 
accompanied with a significantly higher omega-6 to omega-3 PUFA ratio in HIV-infected 
group (5.58±0.57 vs. 3.40±0.31; P=0.028) in favor of inflammatory processes in the body.  
The levels of the omega-3 PUFA in the blood and in the tissues are determined by diet and 
probably also by a genetic component. Changes in the levels of omega-3 PUFA are expected 
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in a given individual after a change in diet and during treatment with omega-3 PUFA. In a 
study (99) of 54 persons with HIV and elevated serum triglycerides (>150 mg/dL) and/or 
abnormal Quantitative Insulin Sensitivity Check Index values (<0.35 but >0.30) in which 
total fat, type of fat, fiber, and glycemic load were controlled along with supplementation 
with n-3 fatty acids to achieve an intake of 6 g/d, serum triglycerides in the intervention 
group decreased from a median of 180 mg/dL to 114 mg/dL from baseline to 3 weeks, 
whereas they remained stable in the control group (P = 0.003). Serum phospholipid fatty 
acids indicated a decrease in de novo lipogenesis and a decrease in arachidonic acid in the 
intervention group. At 3 weeks, the insulin area under the curve decreased but not 
significantly.  
In another randomized placebo-controlled trial (100), 51 patients with HIV infection received 
either 2 capsules of Omacor (an omega-3 PUFA supplement) twice daily or 2 capsules of 
placebo. Plasma triglycerides were reduced in the n-3 PUFA group by 0.14 mmol/l after 12 
weeks of treatment (n=26), while plasma triglycerides increased by 0.36 mmol/l in the 
control group (n=25). There was a significant increase in leukotriene B5 (LTB5) and 
LTB5/LTB4 ratio in the omega-3 PUFA group compared to the control group, inducing anti-
inflammatory effects by increasing formation of anti-inflammatory LTB5.  
Calcium: The importance of dietary calcium in the regulation of body weight and lipid 
metabolism has been the object of scientific investigations throughout the years. This 
relationship was first studied by Zamel et al (101-103), and today it continues to be an object of 
scientific interest (104, 105). Some epidemiological studies show that, in the general population, 
a high calcium and dairy product intake were associated with less fat accumulation and 
higher insulin sensitivity. It also presents an inverse relationship with metabolic syndrome 
components, especially hypertension (106, 107). On the other hand, the results of other 
investigations have indicated that calcium supplementation (1500 mg day−1) did not induce 
changes in body weight or lipid metabolism (108). It has been proposed that low calcium 
intake inhibits lipolysis and stimulates de novo synthesis, reducing fat oxidation, which 
results in an increased waist circumference. Through these mechanisms, a low dietary 
calcium intake leads to weight gain, whereas a high dietary calcium intake exerts the 
opposite effects (104). Another hypothesis suggests that calcium may have a modulating effect 
on the foecal excretion of fats (109). Reports from dietary assessments in the HIV infected 
patients have shown suboptimal intake of calcium (77, 79, 81). In these studies, over 90% of the 
patients did not meet the recommended level of intake of 1000 g/day of calcium. In one 
study, patients who had dietary calcium intake below 700 mg day−1 had greater waist 
circumference and body mass index (BMI) (81). Dairy food consumers (>2 servings per day) 
showed lower BMI (P < 0.01), waist circumference (P = 0.05), systolic and diastolic blood 
pressure, all components of the metabolic syndrome (81).  
Chromium: The metabolic abnormalities reported in PLWH are very similar to the 
abnormalities seen in patients with Type 2 diabetes and in those with chromium (Cr) 
deficiency. Chromium is a nutrient that potentiates insulin action and thus is an essential 
element for glucose and lipid metabolism (110-116). Improvements in glucose tolerance (117-128), 
plasma TG, total and HDL-cholesterol (128-131) after Cr supplementation is well documented 
in humans and in animals. In Type 2 diabetic patients, Cr supplementation resulted in an 
improvement in insulin sensitivity (132-134) and other metabolic parameters (135,136). Studies 
involving patients on total- parenteral- nutrition (TPN) led to conclusive documentation of 
the essential role of Cr in human nutrition (117, 123,124). These patients developed diabetic 
symptoms including glucose intolerance, weight loss, impaired energy utilization, and 
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nerve and brain disorders that were refractory to insulin. After adding Cr to TPN fluids, 
diabetic symptoms were alleviated, and exogenous insulin was no longer required. 
Furthermore, children, the elderly and people with type I and II diabetes mellitus have all 
been shown to display positive effects on blood glucose and lipids in response to 
supplemental Cr (128,129, 136, 137). Finally, in a meta-analysis of 41 randomized trials involving 
1198 participants, Cr supplementation significantly improved glycemia and dyslipidemia 
among patients with diabetes but had no effect in those without diabetes (138).  
The metabolic abnormalities including IR documented in PLWH may be related to 
suboptimal chromium status. We were the first to show (139) that the blood level of Cr was 
significantly lower and the urinary excretion was higher in antiretroviral-treated PLWH 
when compared with healthy control subjects. In a subsequent randomized, double blind, 
placebo-controlled trial (140), 50 HIV-positive subjects with evidence of body fat 
redistribution, elevated lipids or glucose and who were found to have IR based on the 
calculation of homeostatic model of assessment (HOMA= (fasting blood glucose x fasting 
insulin) / 22.5) were randomized to receive either 400 ug of Cr-nicotinate or placebo for a 
period of 16 weeks. For inclusion, the HOMA had to be> 2.5. Body weight and medication 
profile remained stable throughout the study period for both groups. Cr supplementation 
resulted in a significant decrease in blood insulin, blood triglycerides and HOMA. Blood 
glucose, C-peptide, total cholesterol, LDL and HDL cholesterol and Hb A1c remained 
unchanged. Biochemical parameters did not change in the placebo group except for LDL 
cholesterol that increased significantly post supplementation with placebo. In subjects 
supplemented with Cr, those who had body fat redistribution, had a more pronounced drop 
in blood triglycerides (-0.70±0.29 mmol/l) than those without (0.02 ±0.20 mmol/L) 
(P=0.056). The severity of IR at baseline determined the response to Cr supplementation as 
there was a strong correlation between baseline insulin level and the post-supplementation 
drop in blood: insulin (r= -0.852, p= 0.0001), triglycerides (r= -0.602, p=0.001) and c-peptide 
(r= -0.401, p=0.065).  
Analysis by dual energy X-ray absorptiometry (DEXA) scan also showed a significant 
decrease in total body fat mass (kg) in the Cr- supplemented group. This was accompanied 
by a significant reduction in percent total body fat mass and a significant increase in percent 
total lean body mass. Further analysis of the regional fat distribution showed a significant 
decrease in percent trunk fat mass as well as percent fat mass in the arms and legs. In the Cr-
supplemented group, the change in trunk fat mass was much more pronounced in subjects 
with body fat redistribution (-654.6 ±233.7 g) compare to those without this abnormality (-
33.66 ±218.2 g) (P=0.068). As well, in subjects with body fat redistribution, Cr 
supplementation resulted in a decrease in trunk fat mass (-654.6 g ±233.7) whereas in the 
placebo group, trunk fat mass increased (1803±356 g). The difference between the two 
groups was statistically significant (P=0.05). Trunk fat mass correlated significantly with 
waist circumference (r=0.854, p=0.0001), and HOMA at baseline (r=0.275, p=0.036). 
A detailed understanding of the molecular action of Cr is lacking; several lines of evidence 
point to enhancement of insulin action. Chromium increases insulin-stimulated glucose 
uptake in cultured muscle cells (141) and adipocytes (142). Chromium may increase insulin 
binding to cells, insulin receptor number, and insulin receptor tyrosine kinase activity (143). 
The enhancement of insulin action by Cr is associated with phosphorylation of insulin 
receptor substrate-1 (IRS-1) (141) and phosphatidylinositol 3-kinase (PI 3-kinase) (144) and is 
inhibited by wortmanin, an inhibitor of PI 3-kinase. Activation of these proteins in the 
insulin-signalling transduction pathway leads to translocation of glucose transporters from 
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the cytosol to the plasma membrane. Indeed, Cr-picolinate supplementation was shown to 
significantly enhance the membrane-associated Glut-4 content of skeletal muscle and rate of 
glucose disappearance in obese rats after insulin stimulation (145). In a follow-up study it was 
reported that improved glucose disposal rates in Cr-fed, obese, insulin-resistant animals 
were attributable to enhanced insulin-stimulated IRS-1 and PI 3-kinase activity in skeletal 
muscle (146).  
The form or availability of Cr in specific foods is generally not known. A balanced diet will 
provide Cr with an average availability of 1-2% (147,148). Processed meats; liver; whole-grains 
including some ready-to-eat bran cereals; some pulses, such as dried beans; some 
vegetables, including broccoli and mushrooms; and spices are some of the best sources of 
Cr. Dairy products, and most fruits and vegetables, contain low amounts of Cr. Rice and 
sugar are poor sources. 
The suggested safe and adequate intake for Cr is established at 50-200 ug/day for 
adolescents and adults, and 10-120 ug/day for infants and children (149). It is reported that Cr 
intake by even healthy subjects consuming average Westernized diets is suboptimal (150) and 
is below the recommended level of 50 ug. One third of the diets, designed by a nutritionist 
to be well-balanced and to contain the recommended daily intake of vitamins and minerals 
(except chromium) contained less than the minimal safe and adequate intake of 50 ug of Cr 
(151). Anderson and Kozolvsky (150) measured the daily Cr intake of 22 female and 10 male 
subjects for 7 days. Not a single subject had a mean daily Cr intake of 50 ug or more. On the 
other hand, consuming less than 50 ug/d of Cr does not mean that one would eventually 
become Cr deficient. For example, in one study (152), 11 elderly women had an average intake 
of 20.1 ug/day and 11 elderly men had an average intake of 29.8 ug per day; the range of 
intakes was 13.6-47.7 ug among the 22 subjects. Of these, 16 maintained equilibrium, 4 
exhibited positive balances, and 2 exhibited slight and one exhibited severe negative 
balance. The intake at which Cr is low enough to induce changes responsive to Cr 
supplementation is not well established. Moreover, because other substances in the diet 
influence absorption and metabolism of Cr, the point at which Cr intake becomes 
inadequate depends in part on the other foods consumed, medical conditions and 
medication profile.  
Chromium chloride, chromium nicotinate, and chromium picolinate are commonly used 
formulations of trivalent chromium in the supplements. The studies that reported positive 
effects of supplemental chromium on people with diabetes usually involve 400 ug or more 
of Cr.  
Chromium supplements are inexpensive (153), and the limited safety data suggest that Cr is 
safe even at high doses (154). Therefore, Cr supplementation would be an attractive option for 
management of diabetes and for control of insulin and lipid concentration of PLWH. The 
role of Cr supplementation in conjunction with the initiation of HAART should be studied 
prospectively as a cost-effective approach to reducing CVD. 
Physical activity: At the present time, overweight and obese individuals constitute a much 
larger segment of the HIV-infected population than patients with wasting syndrome (155). As 
with individuals in the general population, an obese patient with HIV should be advised 
about the benefits of weight loss and regular physical activity; this is applicable not only to 
patients with high risk of diabetes but also to individuals who have already developed 
glucose intolerance or frank diabetes. There is considerable evidence that lifestyle changes, 
including changes in diet (eg, calorie restriction and reduction in intake of carbohydrates, 
saturated fats, and cholesterol) and increased physical activity can help reverse the 
www.intechopen.com
 
HIV-Infection: The Role of Insulin Resistance and Alternative Treatments 
 
45 
progression to type II diabetes and improve glycemic control in individuals already 
diagnosed with the condition (156-159). In a randomized study, aggressive lifestyle 
modification was more effective than metformin in preventing the development of diabetes 
in individuals with elevated fasting glucose (160); however, adherence to lifestyle changes is 
difficult to maintain over time. The expected improvement in Hb A1C levels in individuals 
who are able to follow lifestyle modification recommendations is 1%-2%, similar to goals 
that are attainable with some drug regimens. 
Clear evidence has established that adults who engage in regular physical activity and/or 
exhibit high cardiorespiratory fitness have a reduced risk of developing type II diabetes (161). 
Furthermore, the beneficial effects of a physically active lifestyle seem to hold true for 
normal-weight, overweight, and obese individuals alike. It is hypothesized that the 
mechanisms underlying this protective effect may be due, at least in part, to the insulin-
sensitizing properties of physical activity on skeletal muscle. 
From controlled studies, exercise training is associated directly with improved insulin 
sensitivity (162-165). Hughes et al (166) showed that exercise training of between 50% and 75% of 
maximal capacity can improve insulin sensitivity in individuals with impaired glucose 
tolerance. From community studies, increased levels of overall habitual physical activity 
have been positively associated with surrogate measures of insulin sensitivity among 
individuals without diabetes (167-168) and among those with impaired glucose tolerance (169), 
independent of obesity. In another study (170), including 1467 men and women of African 
American, Hispanic, and non-Hispanic white ethnicity, aged 40 to 69 years, with glucose 
tolerance ranging from normal to mild non–insulin-dependent diabetes mellitus, increased 
participation in non-vigorous as well as overall and vigorous physical activity was 
associated with significantly higher insulin sensitivity.  
However, questions remain regarding the nature and amount of physical activity required 
to have a sustained, beneficial impact on glucose and insulin metabolism at the individual 
and the community levels. The Centers for Disease Control and Prevention (CDC), and the 
American College of Sports Medicine (ACSM), have recently recommended that every US 
adult should accumulate at least 30 minutes of moderate-intensity physical activity (3 to 6 
metabolic equivalents [METs]) on most, preferably all, days of the week (171). The same 
recommendation was put forth by a 1996 National Institute of Health Consensus Statement 
(172). 
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